Commons Clinic announced a $26 million Series B financing, bringing the total funding to over $60 million. The funding round was led by RA Capital, with participation from Floating Point, SteelSky Ventures, Time BioVentures, Courtside Ventures, and physicians from Commons Clinic.
How the funding will be used: This funding supports the launch of Wholebody by Commons Clinic, a multi-specialty suite that connects all of the organization’s advanced preventive care offerings. Through early detection, tailored prevention, and accountable intervention, Wholebody furthers Common Clinic’s mission to reinvent specialty care.
Wholebody program: Wholebody puts Commons Clinic’s team of renowned specialists at the center of early detection and prevention. Its five specialty programs harness advanced diagnostic technologies to thoroughly evaluate essential health indicators like cardiometabolic wellness, musculoskeletal conditions, women’s health, weight management, hormonal balance, gastrointestinal health, chronic pain, and preventive oncology.
Each patient program includes up to three specialty consults via Commons Clinic’s national expert network and offers priority placement into its vetted “FastPass” network of primary care partners, ensuring patients experience accelerated, contiguous, and highly accountable care.
Whether identifying the BRCA gene in women prompting prophylactic mastectomy in Commons’ surgery centers, detecting unacceptable coronary plaque levels requiring a PCI procedure, or discovering early-stage cancer markers through the Galeri test and facilitating rapid connection to its oncology expert network, Commons Clinic puts patients on immediate, actionable pathways to specialized care.
Leadership: Board-certified cardiologist Dr. Jenica Ortega will lead the Wholebody program, with a specific focus on building its cardiac, metabolic, bariatric, and women’s health service lines. Additionally, Brad Hively, the former CEO of The Oncology Institute, has recently joined Commons’ board to leverage his 25 years of healthcare experience and advise on specialty value-based care strategy and expansion.
Commons has demonstrated success with its care philosophy, centered on prevention and early intervention, through its musculoskeletal care program. This approach has prevented premature surgeries and accelerated the advancement of advanced and high-yield surgical techniques and technologies. And this past year alone, Commons’ Dr. Andrew Wassef performed the first ever Mako robotic revision hip replacement, Dr. Hyun Bae published definitive research on the positive efficacy of allogeneic mesenchymal precursor cells for treatment of chronic low back pain, and Dr. Prem Ramkumar was named Associate Editor at the prestigious Journal of Bone & Joint Surgery.
KEY QUOTES:
“Specialty healthcare too often begins after prevention fails. Patients lack timely access to specialized clinical expertise, leaving conditions to worsen over time before they receive treatment. Equipped with the industry’s most advanced technologies, we are able to quantify health risk, identify specific conditions, and quickly treat issues across the entire body.”
Nick Aubin, co-founder and CEO of Commons Clinic
“At Commons Clinic, we’ve built our foundation as a musculoskeletal center-of-excellence that combines advanced surgical treatments with thoughtful conservative care. Now, we’re applying that same playbook to the entire body, extending our specialty care model into metabolic, cardiac, cancer, and women’s health. This integrated approach is exactly what people need to solve complex health challenges earlier, smarter, and with more precision.”
Ben Schwartz, MD, SVP of Care Services at Commons Clinic
“What sets Commons Clinic apart is its focus on delivering world-class interventional specialty care seamlessly through a vertically integrated model. Through its deep expertise in complex ambulatory surgical care and extraordinary concentration of top-tier specialty talent, Commons Clinic is reimagining the future of specialty care and building the Cleveland Clinic of tomorrow.”
John Loser, Managing Director at Floating Point
